Literature DB >> 24668327

Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.

Xiaochun Liu1, Patricia Lorusso, Monica Mita, Sarina Piha-Paul, David S Hong, Siqing Fu, Lacey McQuinn, Ekaterine Asatiani, Lawrence A Doyle, Helen X Chen, Kenneth R Hess, Razelle Kurzrock, Aung Naing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24668327      PMCID： PMC3983812          DOI： 10.1634/theoncologist.2013-0231

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  13 in total

1.  Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Authors:  Aung Naing; Razelle Kurzrock; Angelika Burger; Sachin Gupta; Xiudong Lei; Naifa Busaidy; David Hong; Helen X Chen; Lawrence A Doyle; Lance K Heilbrun; Eric Rohren; Chaan Ng; Chandtip Chandhasin; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

2.  Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials.

Authors:  Aung Naing
Journal:  Expert Opin Investig Drugs       Date:  2013-04-30       Impact factor: 6.206

3.  A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Authors:  Yasuhito Fujisaka; Yasuhide Yamada; Noboru Yamamoto; Atsushi Horiike; Tomohide Tamura
Journal:  Jpn J Clin Oncol       Date:  2010-04-29       Impact factor: 3.019

4.  CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

Authors:  Kim Margolin; Jeffrey Longmate; Tracey Baratta; Tim Synold; Scott Christensen; Jeffrey Weber; Thomas Gajewski; Ian Quirt; James H Doroshow
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

5.  Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.

Authors:  Aung Naing; Patricia LoRusso; Siqing Fu; David S Hong; Pete Anderson; Robert S Benjamin; Joseph Ludwig; Helen X Chen; Laurence A Doyle; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-03-31       Impact factor: 12.531

6.  Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.

Authors:  Stephen Sonis; Nathaniel Treister; Sant Chawla; George Demetri; Frank Haluska
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

7.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

Review 8.  Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

Authors:  Monica Mita; Kamalesh Sankhala; Issam Abdel-Karim; Alain Mita; Francis Giles
Journal:  Expert Opin Investig Drugs       Date:  2008-12       Impact factor: 6.206

Review 9.  The potential role of mTOR inhibitors in non-small cell lung cancer.

Authors:  Cesare Gridelli; Paolo Maione; Antonio Rossi
Journal:  Oncologist       Date:  2008-02

10.  Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Authors:  J-C Soria; F A Shepherd; J-Y Douillard; J Wolf; G Giaccone; L Crino; F Cappuzzo; S Sharma; S H Gross; S Dimitrijevic; L Di Scala; H Gardner; L Nogova; V Papadimitrakopoulou
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976
View more
  3 in total

1.  Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Authors:  Monica Mita; Siqing Fu; Sarina Anne Piha-Paul; Filip Janku; Alain Mita; Ronald Natale; Wei Guo; Charles Zhao; Razelle Kurzrock; Aung Naing
Journal:  Invest New Drugs       Date:  2017-02-13       Impact factor: 3.850

Review 2.  Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics.

Authors:  Muireann Ní Bhaoighill; Elaine A Dunlop
Journal:  Cancer Drug Resist       Date:  2019-12-19

Review 3.  Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.

Authors:  Cielito C Reyes-Gibby; Stephanie C Melkonian; Jian Wang; Robert K Yu; Samuel A Shelburne; Charles Lu; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Sai-Ching J Yeung; Sanjay Shete
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.